ArticlePsycho-oncology2026
Cognitive Trajectories and Associated Factors in Prostate Cancer Survivors Over a 3-Year Prospective Study.
Article in Psycho-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo identify and characterize cognitive trajectories over 3 years in men with prostate cancer (PCa) and their associated sociodemographic, clinical, and treatment-related factors.
methodsThis study included 454 men with PCa from the NEON-PC cohort. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA), before treatment and at 1- and 3-year follow-ups. Probable cognitive impairment (PCI) was defined using age- and education-adjusted cut-offs. Model-based clustering and clinical interpretability were used to identify cognitive trajectories. Adjusted odds ratios (aORs) were estimated using multinomial logistic regression.
resultsFour cognitive trajectories were identified: (1) consistently high (highest scores throughout follow-up); (2) moderate-stable (stable intermediate scores); (3) moderate-downward (intermediate baseline scores and declining over the follow-up); and (4) consistently low (lowest baseline scores). PCI prevalence increased over time in the moderate-downward trajectory (8.1%-33.3%, p < 0.001) and remained high in the consistently low trajectory (29.8%-32.6%, p = 0.537). Compared with the consistently high trajectory, age (≥ 75 vs. ≤ 65: OR = 4.00; 95% CI: 1.61-9.93), education (≥ 10 vs. ≤ 4 years: aOR = 0.02; 95% CI: 0.01-0.06), and depressive symptoms (per one-point increase in the Hospital Anxiety and Depression Scale: aOR = 1.12; 95% CI: 1.01-1.24) were associated with the consistently low trajectory. Androgen deprivation therapy (ADT) was associated with the moderate-downward trajectory (aOR = 2.33; 95% CI: 1.01-5.36).
conclusionsFour distinct cognitive trajectories were identified among men with PCa over 3 years, with worse trajectories associated with sociodemographic, psychological distress, and treatment-related factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.